One potential implementation for the use of outlier kinase profiling and targeting for clinical management of pancreatic cancer in a precision medicine.

Slides:



Advertisements
Similar presentations
Cedars Sinai Medical Center
Advertisements

Expression profiles for prognosis and prediction Laura J. Van ‘t Veer The Netherlands Cancer Institute, Amsterdam.
Metastatic Breast Cancer: One Size Does Not Fit All Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service MSKCC.
Pharmacogenetics & Pharmacogenomics Personalized Medicine.
D4FF55A0-6B6F BF422A9BA9 Present by: Xiao Chen On December 7, 2015.
San Antonio Breast Cancer Symposium – December 6-10, 2016
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
RNA Quantitation from RNAseq Data
Precision Medicine: The Potential for Identifying Personalized Therapies for Patients with Gastro-Esophageal Cancer.
SI-II A SI-II. Expression analysis of bladder cancer functionally active genes and significantly mutated genes. Comprehensive transcriptome profiling of.
Gene expression.
Sarah Leary, MD MS CBTTC 5/25/2016
 The human genome contains approximately genes.  At any given moment, each of our cells has some combination of these genes turned on & others.
Figure 2 Multiscale modelling in oncology
The Genomics of Cancer and Molecular Testing:
Supplementary Figure 1. A Case no. #1 #2 #3 #5 #6 #7 #8 #9 #10 #11 #13
Oncology Tru Miller White 2.
From Data to Therapies Research in Xinghua Lu’s Lab
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Cytotoxic therapy induces macrophage recruitment, as well as CSF1 and IL-34 mRNA expression. Cytotoxic therapy induces macrophage recruitment, as well.
Nat. Rev. Urol. doi: /nrurol
Preclinical Accelerators of Precision Medicine Todd R. Golub, M.D.
Potential clinical actionability.
Identification of a MEK2 mutation in a melanoma sample resistant to dabrafenib/trametinib. Identification of a MEK2 mutation in a melanoma sample resistant.
Circulating tumor DNA: Solid data from liquid biopsies
Implementing Genome-Driven Oncology
Fig. 5. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic mice. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic.
Clinical applications of CTCs and ctDNA as liquid biopsy for personalized medicine. Clinical applications of CTCs and ctDNA as liquid biopsy for personalized.
RNA sequencing (RNA-Seq) and its application in ovarian cancer
It’s a SMAD/SMAD World Cell
Fig. 1. scRNA-seq applications in cancer medicine.
Precision Medicine A New Era Hazem Assi American University of Beirut
Diverse abnormalities manifest in RNA
Volume 155, Issue 6, Pages (December 2018)
How Can Precision Medicine in Oncology Refine Best Treatment Approach?
Mapping Cancer Origins
Single-Cell Transcriptomic Analysis of Tumor Heterogeneity
Volume 32, Issue 4, Pages e5 (October 2017)
Multiplex Diagnosis of Oncogenic Fusion and MET Exon Skipping by Molecular Counting Using Formalin-Fixed Paraffin Embedded Lung Adenocarcinoma Tissues 
Th1 and CTL-based immune signature and elevated checkpoint expression in MSI colorectal cancer. Th1 and CTL-based immune signature and elevated checkpoint.
773. Detection of RNA Interference (RNAi) Mediated mRNA Cleavage in Fresh Injected Tumor Tissue from Patients in a Phase I Trial of pbi-shRNA™ Lipoplex.
Schematic representation of a transcriptomic evaluation approach.
The Cancer genome atlas (TCGA) and the search for a CUP genetic/epigenetic signature Manel Esteller, MD, PhD. Director, Josep Carreras Leukaemia Research.
Gene expression changes associated with response to combination CPI-444 and anti–PD-L1 treatment in MC38 tumors. Gene expression changes associated with.
EZH2 overexpression establishes a unique and conserved super-enhancer–associated transcriptional landscape. EZH2 overexpression establishes a unique and.
Protein expression profile in a dasatinib-resistant cell line.
MAPJD expression in lung cancers.
l-2HG is elevated in RCC tumors and cell lines.
Sample-wise outlier kinases in ERBB2-positive breast cancer cell lines
Pancreatic cancer cell lines are sensitive to knockdown of outlier kinases. Pancreatic cancer cell lines are sensitive to knockdown of outlier kinases.
Saturation analysis and the discovery of actionability of mutational hotspots. Saturation analysis and the discovery of actionability of mutational hotspots.
Single-cell analyses to tailor treatments
SAF-1 expression in clinical breast cancer tissues.
Transcripts enriched and depleted in NB TICs compared with SKPs and other tumor tissues. Transcripts enriched and depleted in NB TICs compared with SKPs.
Expression of S100A11 in bulk pancreatic tissues (pancreatic cancer, n = 22; IPMN, n = 18; nonneoplastic pancreas, n = 22). Expression of S100A11 in bulk.
Gene expression profiles of T cells.
Extraction diagram of candidate genes identified by global expression analysis. Extraction diagram of candidate genes identified by global expression analysis.
Immunohistochemical staining for FOXO3a of breast cancer tumor tissues
Reduced klotho expression in pancreatic cancer.
MEK1F53L mutation drives clinical acquired resistance to combined RAF/MEK inhibition. MEK1F53L mutation drives clinical acquired resistance to combined.
Possible outcomes of therapeutic treatments using the spiral model.
Identification of general and tissue-specific essential genes.
Group NAME Slogan.
Defining the eTME genes.
mRNA expression of PARP1 in SCLC cell lines and solid tumors.
A, study design for measuring the feasibility, concordance, and accuracy of a plasma-based cfDNA sequencing test compared with biopsy-based sequencing.
BIM expression predicts the response of patients with EGFR-mutant lung cancers. BIM expression predicts the response of patients with EGFR-mutant lung.
Fig. 1. Schematic description of whole-exome or targeted next-generation sequencing analyses. Schematic description of whole-exome or targeted next-generation.
Transcriptome profiling of PD-L1 antibody–treated macrophages showed inflammatory phenotype, increased survival and proliferation, and decreased apoptosis.
Comparison of shRNA scoring approaches.
Presentation transcript:

One potential implementation for the use of outlier kinase profiling and targeting for clinical management of pancreatic cancer in a precision medicine paradigm. One potential implementation for the use of outlier kinase profiling and targeting for clinical management of pancreatic cancer in a precision medicine paradigm. Tumor material that is sampled by biopsy for surgical resection can be used to generate tumor-specific transcriptome data using RNA-seq. To identify outlier kinases, gene expression measures of kinase genes can be extracted and compared with a large compendium of RNA-seq data from reference tissues. Drugs targeting such outlier kinases can then be used alone or in combination with current therapies for individualized treatment of pancreatic cancers. RPKM, reads per thousand base pairs per million reads, refers to normalized absolute gene expression measures for each sample. Srinivasan Yegnasubramanian, and Anirban Maitra Cancer Discovery 2013;3:252-254 ©2013 by American Association for Cancer Research